MEI Pharma, a clinical-stage pharmaceutical company, agreed to merge with Infinity Pharmaceuticals, a biopharmaceutical company. Financial terms were not disclosed. “We are very excited to enter into this agreement with Infinity given the strength of a combined organization that builds on each company’s potential. The combined organization will have three differentiated clinical-stage oncology assets, expected funding into mid-2025 to reach clinical data in all three programs, and a team with extensive oncology clinical development expertise. I believe these ingredients place the merged organization in a strong position to create value for all our stakeholders,” Daniel Gold, MEI Pharma President and CEO.